What is the potential of passive immunotherapy, using antibodies against Pseudomonas aeruginosa virulence factors or surface antigens?

P. aeruginosa infection in the hospital manifests primarily as acute lung infection in patients in intensive care units. Models of pseudomonal pneumonia have ... Antibiotics with a novel mode of action will be needed to avoid cross resistance against currently used therapeutic agents. Importantly, antivirulence drugs are ... Dec 16, 2024 ... ... infection due to P aeruginosa. Secondary outcomes included all ... Pseudomonas aeruginosa infection. Infect Drug Resist. 2022; 15:655 ... Objective. Investigate clonal dissemination of nosocomial multidrug-resistant Pseudomonas aeruginosa isolates within and between Brazilian intensive care ... Nov 5, 2024 ... Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It is the ... Abstract. Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen and a model bacterium for studying virulence and bacterial social traits. While it ... Nov 29, 2023 ... Agent Characteristics Risk Group: RG-2 associated with human disease, rarely serious; preventive or therapeutic interventions often available. Event Description ... 2nd Hands on workshop on Pseudomonas aeruginosa resistance phenotypes and whole genome sequence resistome analysis. Practical course ... Pseudomonas aeruginosa strain Boston 41501 was isolated from blood culture. This whole-genome sequenced bacterial strain has applications in media and ... Pseudomonas aeruginosa is the most common strain that causes infections in humans. Around 13% of P. aeruginosa infections are multidrug-resistant (MDR-PA). Mild ...